Search Results 231-240 of 17445 for Mmol

1. A Study of MCLA-128 in Patients with Solid Tumors Harboring an NRG1 Fusion - Mayo Clinic

   Hemoglobin ≥ 8 g/dL or ≥ 5 mmol/L;; Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN) and total bilirubin ...

2. A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations - Mayo Clinic

   Potassium ≥ 3.6 mmol/L or within institutional normal limits;; Phosphate ≤ 1.5 x ULN. Able to swallow, retain, and absorb oral medications. Exclusion ...

3. Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen - Mayo Clinic

   Poorly controlled diabetes mellitus defined as having a HbA1c ≥8.5% (ie, ≥69.5 mmol/mol) or estimated HbA1c based on fructosamine if HbA1c is not ...

4. Robotic surgery - Doctors & Departments - Mayo Clinic

   Robotic systems can help surgeons increase precision, flexibility and control for many procedures. Learn about the advantages and availability of ...

5. A Study of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment for Patients with Stage IIIB/IV Non-Small Cell Lung Cancer - Mayo Clinic

   Serum sodium level is ≥ 130 mmol/L. Has an EGFR activating mutation (exon 19 deletion or exon 21 L858R), with or without T790M mutation by local or central ...

6. A Study to Evaluate the Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia - Mayo Clinic

   Low potassium (< 3 mmol/L). Creatinine (> 5.0 mg/dl or < 0.6 mg/dl). Unable to exercise due primarily to orthopedic limitation. Severe lung disease. Morbid ...

7. A Study To Evaluate Atumelnant In Adults With Congenital Adrenal Hyperplasia - Mayo Clinic

   Poorly controlled diabetes mellitus defined as having an HbA1c ≥8.5% (≥69 mmol/mL) or estimated HbA1c based on fructosamine if HbA1c is not evaluable (eg ...

8. Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Urine protein/creatinine ratio (UPCR) ≤ 1 mg/mg (≤ 113.2 mg/mmol). For subjects with UC: ≤ 2 mg/mg (≤ 226.4 mg/mmol) creatinine. Capable of ...

9. Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer - Mayo Clinic

   Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L. Total Bilirubin ≤ 1.5 x ULN. Bilirubin for patients w/Gilbert's ≤ 3.0 x ULN. Calc. Creatinine Clearance > 20 ml/min ...

10. A Study of Lenvatinib for Treating Patients with Metastatic or Advanced Pheochromocytoma or Paraganglioma that Cannot be Removed by Surgery - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL (5.6 mmol/L); NOTE: transfusions are not allowed ≤ 7 days prior to registration; Total bilirubin ≤ 1.5 X upper limit of normal (ULN) ...